Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.

Liu, Guoqiang; Kang, Shuo; Wang, Xinchen; Shang, Fangjian

Liu, Guoqiang; Kang, Shuo; Wang, Xinchen; Shang, Fangjian.

Afiliación

Liu G; Department of Pharmacy, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Kang S; Department of Pharmacy, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Wang X; Laboratory of Pathology, Hebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Shang F; Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, China.

Front Oncol ; 11: 669195, 2021.

Article en En | MEDLINE | ID: mdl-33987103

Palabras clave

atezolizumab; chemotherapy; cost-effectiveness; first-line treatment; non-small-cell lung cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google